Enhancer	O
transcripts	O
mark	O
active	O
estrogen	B-TFBS
receptor	I-TFBS
binding	I-TFBS
sites	E-TFBS
.	O


We	O
have	O
integrated	O
and	O
analyzed	O
a	O
large	O
number	O
of	O
data	O
sets	O
from	O
a	O
variety	O
of	O
genomic	O
assays	O
using	O
a	O
novel	O
computational	O
pipeline	O
to	O
provide	O
a	O
global	O
view	O
of	O
estrogen	O
receptor	O
1	O
(	O
ESR1	O
;	O
a	O
.	O
k	O
.	O
a	O
.	O


ERalpha	O
)	O
enhancers	O
in	O
MCF	O
-	O
7	O
human	O
breast	O
cancer	O
cells	O
.	O


Using	O
this	O
approach	O
,	O
we	O
have	O
defined	O
a	O
class	O
of	O
primary	O
transcripts	O
(	O
eRNAs	O
)	O
that	O
are	O
transcribed	O
uni	O
-	O
or	O
bidirectionally	O
from	O
estrogen	B-TFBS
receptor	I-TFBS
binding	I-TFBS
sites	E-TFBS
(	O
ERBSs	S-TFBS
)	O
with	O
an	O
average	O
transcription	O
unit	O
length	O
of	O
~	O
3	O
-	O
5	O
kb	O
.	O


The	O
majority	O
are	O
up	O
-	O
regulated	O
by	O
short	O
treatments	O
with	O
estradiol	O
(	O
i	O
.	O
e	O
.	O
,	O
10	O
,	O
25	O
,	O
or	O
40	O
min	O
)	O
with	O
kinetics	O
that	O
precede	O
or	O
match	O
the	O
induction	O
of	O
the	O
target	O
genes	O
.	O


The	O
production	O
of	O
eRNAs	O
at	O
ERBSs	S-TFBS
is	O
strongly	O
correlated	O
with	O
the	O
enrichment	O
of	O
a	O
number	O
of	O
genomic	O
features	O
that	O
are	O
associated	O
with	O
enhancers	O
(	O
e	O
.	O
g	O
.	O
,	O
H3K4me1	O
,	O
H3K27ac	O
,	O
EP300	O
/	O
CREBBP	O
,	O
RNA	O
polymerase	O
II	O
,	O
open	O
chromatin	O
architecture	O
)	O
,	O
as	O
well	O
as	O
enhancer	O
looping	O
to	O
target	O
gene	O
promoters	O
.	O


In	O
the	O
absence	O
of	O
eRNA	O
production	O
,	O
strong	O
enrichment	O
of	O
these	O
features	O
is	O
not	O
observed	O
,	O
even	O
though	O
ESR1	O
binding	O
is	O
evident	O
.	O


We	O
find	O
that	O
flavopiridol	O
,	O
a	O
CDK9	O
inhibitor	O
that	O
blocks	O
transcription	O
elongation	O
,	O
inhibits	O
eRNA	O
production	O
but	O
does	O
not	O
affect	O
other	O
molecular	O
indicators	O
of	O
enhancer	O
activity	O
,	O
suggesting	O
that	O
eRNA	O
production	O
occurs	O
after	O
the	O
assembly	O
of	O
active	O
enhancers	O
.	O


Finally	O
,	O
we	O
show	O
that	O
an	O
enhancer	O
transcription	O
"	O
signature	O
"	O
based	O
on	O
GRO	O
-	O
seq	O
data	O
can	O
be	O
used	O
for	O
de	O
novo	O
enhancer	O
prediction	O
across	O
cell	O
types	O
.	O


Together	O
,	O
our	O
studies	O
shed	O
new	O
light	O
on	O
the	O
activity	O
of	O
ESR1	O
at	O
its	O
enhancer	O
sites	O
and	O
provide	O
new	O
insights	O
about	O
enhancer	O
function	O
.	O
